Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.

Publication Year: 2023

DOI:
10.1007/s15010-023-02074-z

PMCID:
PMC10665230

PMID:
37462895

Journal Information

Full Title: Infection

Abbreviation: Infection

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestThe authors have no competing interests to declare that are relevant to the content of this article. Ethical approvalResearch was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The study protocol was approved by the local ethics committees of both centres (approval number of the leading ethics committee “JUH” No. 2020-1957). Due to the retrospective nature of the study the need for informed consent was waved. Conflict of interest The authors have no competing interests to declare that are relevant to the content of this article."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL. Internal funding."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025